Thursday 16 October, 2025
Background: Tuberculosis (TB) remains the most deadly infectious disease in the 21st century. Due to lengthy treatment, adverse effects and…
Read morePoster: Drug/Disease Modelling - Infection
A PKPD model of ribavirin in Lassa virus infected mice
Thursday 16 October, 2025
Objectives: Ribavirin is a broad-spectrum antiviral, which is used in the therapy of the Lassa fever. In vitro ribavirin showed…
Read moreModelling rate and extent of resistance development against colistin in Klebsiella pneumoniae and Pseudomonas aeruginosa
Thursday 16 October, 2025
Objectives: Klebsiella pneumonia (KP) and Pseudomonas aeruginosa (PA) are commonly associated with serious life-threatening infections and antibiotic resistance1. Colistin is…
Read morePopulation plasma and tissue pharmacokinetics of linezolid in healthy volunteers and septic patients
Thursday 16 October, 2025
Background: Linezolid, an antimicrobial drug, is commonly used to treat bacterial pneumonia and skin and soft tissue structure infections (SSTIs)…
Read moreModelling rate and extent of resistance development against colistin in Klebsiella pneumoniae
Thursday 16 October, 2025
Objectives: Klebsiella pneumonia is a gram-negative pathogen of concern due to widespread multidrug resistance [1]. Colistin is one of the last…
Read morePopulation pharmacokinetic modeling of ceftaroline characterizing tissue distribution following different ceftaroline fosamil infusion regimens to volunteers undergoing muscle and subcutaneous tissue microdialysis
Thursday 16 October, 2025
Objectives: Ceftaroline fosamil (CPT-F), the prodrug of the β‐lactam ceftaroline (CPT), is a fifth-generation cephalosporine approved for the treatment of acute…
Read moreUnexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin.
Thursday 16 October, 2025
Objectives: Rifampicin (RIF) is the key component of first-line regimens for drug‑susceptible tuberculosis (TB), with a concentration-dependent bactericidal effect (1)….
Read morePopulation pharmacokinetic analysis of the drug interaction between ritonavir-boosted atazanavir and rifampicin
Thursday 16 October, 2025
Introduction: Boosted protease inhibitors like atazanavir/ritonavir (ATV/r) are commonly prescribed as second-line antiretroviral therapy (ART) for HIV in low-income countries. However,…
Read moreInterspecies scaling of host inflammatory response during infection
Thursday 16 October, 2025
Introduction: Sepsis is defined as a life-threatening condition that is caused by an disregulated host response to an infection, and…
Read morePopulation pharmacokinetics of itraconazole and hydroxy-itraconazole following administration of an intravenous nanocrystal formulation
Thursday 16 October, 2025
Introduction: Itraconazole is a broad-spectrum antifungal agent used to treat various fungal infections, including aspergillosis, and for prophylaxis of invasive fungal…
Read more